Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells

Clinical and Experimental Medicine

Volumn 16, Issue 1, 2016, Pages 37-47

  Sun, Kai ^a   Duan, Xiaoyi ^a   Cai, Hui ^a   Liu, Xiaohong ^b   Yang, Ya ^a   Li, Min ^a   Zhang, Xiaoyun ^b   Wang, Jiansheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Breast cancer; Curcumin; Invasion; Lysophosphatidic acid

Indexed keywords

CURCUMIN; GELATINASE A; GELATINASE B; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; LYSOPHOSPHOLIPID; RHOA PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL PROLIFERATION; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CURCUMIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYSOPHOSPHOLIPIDS; MATRIX METALLOPROTEINASES; MCF-7 CELLS; NEOPLASM INVASIVENESS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84957948424     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0336-7     Document Type: Article

References (41)

1. Engelhardt EG, Garvelink MM, de Haes JH, van der Hoeven JJ, Smets EM, Pieterse AH, et al. Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol. 2014;32(3):238–50. doi:10.1200/JCO.2013.50.3417.
2. Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy EP. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol. 2011;29(12):1570–7. doi:10.1200/JCO.2010.33.0472.
3. Petekkaya I, Ayyildiz V, Kizilarslanoglu MC, Sahin U, Gezgen G, Roach EC, et al. Prognosis of breast cancer in patients with peritoneal metastasis. Breast. 2012;21(3):420–1. doi:10.1016/j.breast.2012.02.008.
4. Cai H, Xu Y. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal. 2013;11(1):31. doi:10.1186/1478-811X-11-31.
5. Swamydas M, Nguyen D, Allen LD, Eddy J, Dreau D. Progranulin stimulated by LPA promotes the migration of aggressive breast cancer cells. Cell Commun Adhes. 2011;18(6):119–30. doi:10.3109/15419061.2011.641042.
6. Sedlakova I, Vavrova J, Tosner J, Hanousek L. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer. Tumour Biol. 2011;32(2):311–6. doi:10.1007/s13277-010-0123-8.
7. Du J, Sun C, Hu Z, Yang Y, Zhu Y, Zheng D, et al. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS One. 2010;5(12):0015940.
8. Mierke CT, Bretz N, Altevogt P. Contractile forces contribute to increased glycosylphosphatidylinositol-anchored receptor CD24-facilitated cancer cell invasion. J Biol Chem. 2011;286(40):34858–71.
9. Alemayehu M, Dragan M, Pape C, Siddiqui I, Sacks DB, Di Guglielmo GM, et al. beta-Arrestin2 regulates lysophosphatidic acid-induced human breast tumor cell migration and invasion via Rap1 and IQGAP1. PLoS One. 2013;8(2):6.
10. Hama K, Aoki J. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid. Prog Lipid Res. 2010;49(4):335–42. doi:10.1016/j.plipres.2010.03.001.
11. Mikelis CM, Palmby TR, Simaan M, Li W, Szabo R, Lyons R, et al. PDZ-RhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation. J Biol Chem. 2013;288(17):12232–43. doi:10.1074/jbc.M112.428599.
12. Mingle LA, Bonamy G, Barroso M, Liao G, Liu G. LPA-induced mutually exclusive subcellular localization of active RhoA and Arp2 mRNA revealed by sequential FRET and FISH. Histochem Cell Biol. 2009;132(1):47–58. doi:10.1007/s00418-009-0589-x.
13. He M, Cheng Y, Li W, Liu Q, Liu J, Huang J, et al. Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer. 2010;10:170. doi:10.1186/1471-2407-10-170.
14. Abecassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res. 2003;291(2):363–76.
15. Noorafshan A, Ashkani-Esfahani S. A review of therapeutic effects of curcumin. Curr Pharm Des. 2013;19(11):2032–46.
16. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17(3):190–7.
17. Lv ZD, Liu XP, Zhao WJ, Dong Q, Li FN, Wang HB, et al. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol. 2014;7(6):2818–24.
18. Meiyanto E, Putri DD, Susidarti RA, Murwanti R, Sardjiman AF, et al. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev. 2014;15(1):179–84.
19. Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/beta-catenin negative feedback loop. Stem Cell Res Ther. 2014;5(5):116.
20. Li X, Xie W, Xie C, Huang C, Zhu J, Liang Z, et al. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res. 2014;28(10):1553–60.
21. Mo N, Li ZQ, Li J, Cao YD. Curcumin inhibits TGF-beta1-induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA- MB-231 cells. Asian Pac J Cancer Prev. 2012;13(11):5709–14.
22. Kim JH, Adelstein RS. LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol. 2011;226(11):2881–93. doi:10.1002/jcp.22631.
23. Fagan-Solis KD, Schneider SS, Pentecost BT, Bentley BA, Otis CN, Gierthy JF, et al. The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem. 2013;114(6):1385–94. doi:10.1002/jcb.24480.
24. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279(8):6595–605. doi:10.1074/jbc.M308133200.
25. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269(2):199–225. doi:10.1016/j.canlet.2008.03.009.
26. Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23(1):103–12. doi:10.1007/s10552-011-9859-8.
27. Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, et al. Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol. 2013;183(4):1084–95. doi:10.1016/j.ajpath.2013.06.012.
28. Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell. 2013;105(8):317–33. doi:10.1111/boc.201300011.
29. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157–86. doi:10.1146/annurev.pharmtox.010909.105753.
30. Moolenaar WH. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol. 1994;4(6):213–9.
31. Li ZW, Zhao YR, Zhao C, Fu R, Li ZY. Function and biological activities of the autotaxin-LPA axis. Sheng Li Xue Bao. 2011;63(6):601–10.
32. Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol. 2009;5(10):1659–73. doi:10.2217/fon.09.120.
33. Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 2011;30(3–4):557–65. doi:10.1007/s10555-011-9319-7.
34. Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res. 1999;253(1):230–8. doi:10.1006/excr.1999.4702.
35. Wang Q, Liu M, Kozasa T, Rothstein JD, Sternweis PC, Neubig RR. Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J Biol Chem. 2004;279(28):28831–4. doi:10.1074/jbc.C400105200.
36. Liu S. The ROCK signaling and breast cancer metastasis. Mol Biol Rep. 2011;38(2):1363–6. doi:10.1007/s11033-010-0238-4.
37. Zheng SQ, Huang RQ, Zhang YJ. Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer. Zhonghua Bing Li Xue Za Zhi. 2010;39(4):240–4.
38. Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22(3):237–46. doi:10.1007/s10585-005-8115-6.
39. Schram K, Ganguly R, No EK, Fang X, Thong FS, Sweeney G. Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to enhanced cell migration. Endocrinology. 2011;152(5):2037–47. doi:10.1210/en.2010-1166.
40. Liu X, Chen D, Liu G. Overexpression of RhoA promotes the proliferation and migration of cervical cancer cells. Biosci Biotechnol Biochem. 2014;. doi:10.1080/09168451.2014.943650.
41. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16(6):4567–98. doi:10.3390/molecules16064567.